51 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Immunology & Infectious Disease Video PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care

    Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care

    Visit https://www.peervoice.com/RVW860 to view the entire programme with slides. After completing “Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care”, participants will be able to: Discuss the pathogenic mechanisms in severe eosinophilic asthma and the role of biomarkers in informing treatment; Describe the role of biologics in improving patient outcomes and their impact on background medication use; and Outline the most recent real-world evidence with biologics for severe eosinophilic asthma and its clinical implications for patient management.

    • 26 min
    • video
    George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

    George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

    Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.

    • 11 min
    • video
    Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care

    Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care

    Visit https://www.peervoice.com/DPR860 to view the entire programme with slides. After completing “Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care”, participants will be able to: Discuss how technology has been used to optimise care of chronic diseases; Recognise the needs for simplifying the management of immunoglobulin therapy using device and digital technologies; and Identify technologies that are in development to support patient-integrated care for those requiring immunoglobulin therapy and key considerations for their implementation.

    • 50 min
    • video
    Sharon Walmsley, CM, MSc, MD - Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey

    Sharon Walmsley, CM, MSc, MD - Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey

    Visit https://www.peervoice.com/SGG860 to view the entire programme with slides. After completing “Sharon Walmsley, CM, MSc, MD - Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey”, participants will be able to: Identify patient and antiretroviral therapy (ART) characteristics that may influence decisions on which ART regimen to initiate in people with HIV at initial diagnosis; Translate the clinical data on the impact of ART on the risk of birth defects in context of current clinical recommendations for viral suppression of HIV in pregnant individuals; Use the benefits and limitations of long-acting injectable antiretroviral therapy (LAI-ART) to identify which people living with HIV may be appropriate for LAI-ART; and Explain the impact of age-related changes such as menopause and cognitive decline on the clinical management of people living with HIV.

    • 1 hr 17 min
    • video
    Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH

    Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH

    Visit https://www.peervoice.com/ERK860 to view the entire programme with slides. After completing “Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH”, participants will be able to: Outline the latest treatment guidelines for people living with HIV (PLWH) who are coinfected with hepatitis B virus (HBV); Summarise the benefits and limitations of current therapies for HIV/HBV coinfection; and Assess the latest clinical data for HIV regimens for treatment of HIV/HBV coinfection.

    • 26 min
    • video
    John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients?

    John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients?

    Visit https://www.peervoice.com/THE860 to view the entire programme with slides. After completing “John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients?”, participants will be able to: Explain the mechanism of action of anti-IL-23 therapies in ulcerative colitis (UC); Evaluate the latest clinical evidence with anti-IL-23 agents in UC; Discuss evolving treatment goals and definitions of remission in patients with UC; and Define the potential role of anti-IL-23 agents in patients with UC, based on the latest evidence.

    • 17 min

Top Podcasts In Science

The Infinite Monkey Cage
BBC Radio 4
The We Society
AcSS
Oceans: Life Under Water
Crowd Network | Greenpeace UK
Hidden Brain
Hidden Brain, Shankar Vedantam
Science Weekly
The Guardian
Child
BBC Radio 4

More by PeerVoice

PeerVoice Digestive Diseases Video
PeerVoice
PeerVoice Heart & Lung Audio
PeerVoice
PeerVoice Endocrinology & Metabolic Disorders Video
PeerVoice
PeerVoice Immunology & Infectious Disease Audio
PeerVoice
PeerVoice Heart & Lung Video
PeerVoice
PeerVoice Oncology & Haematology Video
PeerVoice